Selective laser trabeculoplasty: current perspectives

Kate E Leahy,1 Andrew JR White1–3 1Westmead Hospital, Westmead, NSW, Australia; 2Centre for Vision Research, Westmead Millennium Institute, University of Sydney, Sydney, NSW, Australia; 3Save Sight Institute, University of Sydney, Sydney, NSW, Australia Abstract: Selective laser trabecul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Leahy KE, White AJR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/50507a3a3f2348548b6bb88c841bebd2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:50507a3a3f2348548b6bb88c841bebd2
record_format	dspace
spelling	oai:doaj.org-article:50507a3a3f2348548b6bb88c841bebd22021-12-02T00:42:21ZSelective laser trabeculoplasty: current perspectives1177-5483https://doaj.org/article/50507a3a3f2348548b6bb88c841bebd22015-05-01T00:00:00Zhttp://www.dovepress.com/selective-laser-trabeculoplasty-current-perspectives-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kate E Leahy,1 Andrew JR White1–3 1Westmead Hospital, Westmead, NSW, Australia; 2Centre for Vision Research, Westmead Millennium Institute, University of Sydney, Sydney, NSW, Australia; 3Save Sight Institute, University of Sydney, Sydney, NSW, Australia Abstract: Selective laser trabeculoplasty (SLT) has been used in the treatment of glaucoma for just over a decade. Here, we review the current literature in terms of suggested mechanism, efficacy, method of treatment, predictors of success, adverse events, repeatability, and cost of SLT. The exact mechanism by which SLT lowers intraocular pressure (IOP) remains unknown although circumstantial evidence has come in many forms in relation to structural alteration; oxidative stress and inflammatory responses; tight junction integrity; proliferative responses; and microbubble formation. SLT is as effective as argon laser trabeculoplasty and medications in reducing IOP in glaucoma and ocular hypertension. The treatment is not uniformly effective in all eyes, and its IOP-lowering effect decreases over time. High pretreatment IOP is the strongest predictor of success; however, significant pressure reduction has also been shown in normal-tension glaucoma and in patients already taking multiple antiglaucoma drops. Mild, transient adverse effects are common. Transient IOP spikes usually resolve quickly with or without antiglaucoma treatment but may be problematic in pigmented angles. The limited available evidence suggests SLT is repeatable and cost-effective for the treatment of glaucoma and ocular hypertension. Keywords: glaucoma, SLT, ocular hypertension, intraocular pressureLeahy KEWhite AJRDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 833-841 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Leahy KE White AJR Selective laser trabeculoplasty: current perspectives
description	Kate E Leahy,1 Andrew JR White1–3 1Westmead Hospital, Westmead, NSW, Australia; 2Centre for Vision Research, Westmead Millennium Institute, University of Sydney, Sydney, NSW, Australia; 3Save Sight Institute, University of Sydney, Sydney, NSW, Australia Abstract: Selective laser trabeculoplasty (SLT) has been used in the treatment of glaucoma for just over a decade. Here, we review the current literature in terms of suggested mechanism, efficacy, method of treatment, predictors of success, adverse events, repeatability, and cost of SLT. The exact mechanism by which SLT lowers intraocular pressure (IOP) remains unknown although circumstantial evidence has come in many forms in relation to structural alteration; oxidative stress and inflammatory responses; tight junction integrity; proliferative responses; and microbubble formation. SLT is as effective as argon laser trabeculoplasty and medications in reducing IOP in glaucoma and ocular hypertension. The treatment is not uniformly effective in all eyes, and its IOP-lowering effect decreases over time. High pretreatment IOP is the strongest predictor of success; however, significant pressure reduction has also been shown in normal-tension glaucoma and in patients already taking multiple antiglaucoma drops. Mild, transient adverse effects are common. Transient IOP spikes usually resolve quickly with or without antiglaucoma treatment but may be problematic in pigmented angles. The limited available evidence suggests SLT is repeatable and cost-effective for the treatment of glaucoma and ocular hypertension. Keywords: glaucoma, SLT, ocular hypertension, intraocular pressure
format	article
author	Leahy KE White AJR
author_facet	Leahy KE White AJR
author_sort	Leahy KE
title	Selective laser trabeculoplasty: current perspectives
title_short	Selective laser trabeculoplasty: current perspectives
title_full	Selective laser trabeculoplasty: current perspectives
title_fullStr	Selective laser trabeculoplasty: current perspectives
title_full_unstemmed	Selective laser trabeculoplasty: current perspectives
title_sort	selective laser trabeculoplasty: current perspectives
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/50507a3a3f2348548b6bb88c841bebd2
work_keys_str_mv	AT leahyke selectivelasertrabeculoplastycurrentperspectives AT whiteajr selectivelasertrabeculoplastycurrentperspectives
_version_	1718403494488047616

Selective laser trabeculoplasty: current perspectives

Ejemplares similares